Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial

VANISH Investigators

Abstract

Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and increased risk of heart failure and arrhythmias. There are no existing therapies to modify disease progression. In this study, we conducted a multi-center, double-blind, placebo-controlled phase 2 clinical trial to assess the safety and efficacy of the angiotensin II receptor blocker valsartan in attenuating disease evolution in early HCM. In total, 178 participants with early-stage sarcomeric HCM were randomized (1:1) to receive valsartan (320 mg daily in adults; 80-160 mg daily in children) or placebo for 2 years ( NCT01912534 ). Standardized changes from baseline to year 2 in LV wall thickness, mass and volumes; left atrial volume; tissue Doppler diastolic and systolic velocities; and serum levels of high-sensitivity troponin T and N-terminal pro-B-type natriuretic protein were integrated into a single composite z-score as the primary outcome. Valsartan (n = 88) improved cardiac structure and function compared to placebo (n = 90), as reflected by an increase in the composite z-score (between-group difference +0.231, 95% confidence interval (+0.098, +0.364); P = 0.001), which met the primary endpoint of the study. Treatment was well-tolerated. These results indicate a key opportunity to attenuate disease progression in early-stage sarcomeric HCM with an accessible and safe medication.

OriginalsprogEngelsk
TidsskriftNature Medicine
Vol/bind27
Udgave nummer10
Sider (fra-til)1818-1824
Antal sider7
ISSN1078-8956
DOI
StatusUdgivet - okt. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater